MERCK & CO INC (MRK)
NYSE • Healthcare
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About MERCK & CO INC
Merck & Co., Inc., listed on the NYSE under MRK, develops and markets human and animal health products as a global biopharmaceutical company. It operates in the drugmaking business, with FY2025 revenue of $64.9 billion, through a Pharmaceuticals segment focused on medicines and vaccines for people and an Animal Health segment serving veterinary care and livestock markets.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
MERCK & CO INC's Technical Indicators Summary
Merck’s technical picture is bullish with price well above short, medium and long moving averages and multiple momentum indicators showing strength, including a positive MACD and elevated RSI. ADX registers moderate trend strength, suggesting the advance has some conviction, while ATR is muted relative to price, indicating controlled volatility. On-balance volume is supportive, and the pivot sits near the current level but does not undermine the trend. Technical takeaway: Strong Buy — broad moving average support, constructive momentum and confirming volume underpin the bullish stance.
| Indicator | Value |
|---|---|
RSI (14) | 65.85 |
Stochastic %K (14, 3, 3) | 87.97 |
CCI (20) | 161.47 |
WPR (14) | -23.81 |
Momentum (10) | 7.18 |
MFI | 68.97 |
MACD Level (12, 26) | 2.53 |
Bollinger Bands | $125.45 - $136.53 |
ATR (14) | $3.24 (2.40%) |
ADX (14) | 23.59 |
OBV | 143,706,685 |
Classic Pivot Point | $135.90 |
Fibonacci Pivot Point | $135.90 |
Simple Moving Averages | $114.30 - $132.21(5 indicators) |
Exponential Moving Averages | $112.90 - $133.08(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The session wrapped with MRK mildly under yesterday, holding a -0.58% gap down. The session closed with mild sector strength (1.59%), slightly supporting risk appetite. MRK gains a potential upside from higher 2026 sales outlook and new KEYTRUDA combo approval in Canada.
Trading Volume
Below 10d avg (8.2M)
8.1M
vs S&P 500 Today
Inline with Market
+0.02%
52-Week Position
Near highs
95.4%
Updated: August 18, 2026 at 20:43 UTC
Quote Summary
MRK Headlines
FDA clears Merck’s oral PCSK9 drug LIPFENDRA
July 16, 2026
StockStory flags several stocks for caution
March 24, 2026
Institutions Shift Positions In Major Health Stocks
February 27, 2026
Markets, macro and company updates on Feb. 18, 2026
February 18, 2026